Premium
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
Author(s) -
Simrén Joel,
Leuzy Antoine,
Karikari Thomas K.,
Hye Abdul,
Benedet Andréa Lessa,
LanteroRodriguez Juan,
MattssonCarlgren Niklas,
Schöll Michael,
Mecocci Patrizia,
Vellas Bruno,
Tsolaki Magda,
Kloszewska Iwona,
Soininen Hilkka,
Lovestone Simon,
Aarsland Dag,
Hansson Oskar,
RosaNeto Pedro,
Westman Eric,
Blennow Kaj,
Zetterberg Henrik,
Ashton Nicholas J.
Publication year - 2021
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.12283
Subject(s) - dementia , biomarker , cognitive decline , medicine , oncology , pathology , disease , alzheimer's disease , gastroenterology , chemistry , biochemistry
This study investigated the diagnostic and disease‐monitoring potential of plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia and cognitively unimpaired (CU) individuals. Methods Plasma was analyzed using Simoa assays from 99 CU, 107 MCI, and 103 AD dementia participants. Results Phosphorylated‐tau181 (P‐tau181), neurofilament light, amyloid‐β (Aβ42/40), Total‐tau and Glial fibrillary acidic protein were altered in AD dementia but P‐tau181 significantly outperformed all biomarkers in differentiating AD dementia from CU (area under the curve [AUC] = 0.91). P‐tau181 was increased in MCI converters compared to non‐converters. Higher P‐tau181 was associated with steeper cognitive decline and gray matter loss in temporal regions. Longitudinal change of P‐tau181 was strongly associated with gray matter loss in the full sample and with Aβ measures in CU individuals. Discussion P‐tau181 detected AD at MCI and dementia stages and was strongly associated with cognitive decline and gray matter loss. These findings highlight the potential value of plasma P‐tau181 as a non‐invasive and cost‐effective diagnostic and prognostic biomarker in AD.